To include your compound in the COVID-19 Resource Center, submit it here.

Tragara reports Capoxigem data

Tragara Pharmaceuticals Inc. (San Diego, Calif.) said Capoxigem apricoxib plus erlotinib missed the primary endpoint of significantly improving time to disease

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE